Clinically Relevant Prognostic Markers for Prostate Cancer: The Search Goes On
Authors: Edward P. Gelmann
Journal: Annals of Internal Medicine (2009)

Editorials5 May 2009Clinically Relevant Prognostic Markers for Prostate Cancer: The Search Goes OnEdward P. Gelmann, MD and Susan M. Henshall, PhDEdward P. Gelmann, MDFrom Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, and Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales 2010, Australia.Search for more papers by this author and Susan M. Henshall, PhDFrom Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, and Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales 2010, Australia.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-150-9-200905050-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The management of early-stage prostate cancer continues to present both diagnostic and therapeutic dilemmas to primary care physicians and specialists alike. Prostate cancer alone accounted for about 25% of incident cancer cases in men in the United States in 2008 (1). Based on cases diagnosed from 1996 to 2003, an estimated 91% of these men with newly diagnosed cases are likely to have stage 1 or 2 disease, for which 5-year relative survival chances approach 100%. With such a favorable prognosis, some question the benefit of exposing men with early-stage and low- or moderate-grade prostate cancer to radical therapy (2). ...References1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. [PMID: 18287387] CrossrefMedlineGoogle Scholar2. Scardino PT. Localized prostate cancer is rarely a fatal disease [Editorial]. Nat Clin Pract Urol. 2008;5:1. [PMID: 18185510] CrossrefMedlineGoogle Scholar3. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, et al; Scandinavian Prostate Cancer Group Study Number 4. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008;100:1144-54. [PMID: 18695132] CrossrefMedlineGoogle Scholar4. Andriole GL, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-9. [PMID: 19297565] CrossrefMedlineGoogle Scholar5. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8. [PMID: 19297566] CrossrefMedlineGoogle Scholar6. Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L, et al; EORTC 22911. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol. 2007;25:4178-86. [PMID: 17878474] CrossrefMedlineGoogle Scholar7. Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol. 2007;25:110-4. [PMID: 17349524] CrossrefMedlineGoogle Scholar8. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956-62. [PMID: 19167731] CrossrefMedlineGoogle Scholar9. Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol. 1994;18:796-803. [PMID: 8037294] CrossrefMedlineGoogle Scholar10. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol. 1997;21:566-76. [PMID: 9158682] CrossrefMedlineGoogle Scholar11. Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, et al. Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer. 1998;83:1995-2002. [PMID: 9806659] CrossrefMedlineGoogle Scholar12. Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Ann Intern Med. 2009;150:595-603. LinkGoogle Scholar13. Krupski T, Petroni GR, Frierson HF, Theodorescu JU. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology. 2000;55:743-9. [PMID: 10792093] CrossrefMedlineGoogle Scholar14. Concato J. What will the emperor say?: screening for prostate cancer as of 2008. Cancer J. 2009;15:7-12. [PMID: 19197166] CrossrefMedlineGoogle Scholar15. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374-83. [PMID: 19276453] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, and Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales 2010, Australia.Disclosures: None disclosed.Corresponding Author: Edward P. Gelmann, MD, Columbia University, Milstein Hospital Building, 6N-435, 177 Fort Washington Avenue, New York, NY 10032; e-mail, [email protected]edu.Current Author Addresses: Dr. Gelmann: Columbia University, Milstein Hospital Building, 6N-435, 177 Fort Washington Avenue, New York, NY 10032.Dr. Henshall: Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMolecular Markers and Death From Prostate Cancer John Concato , Dhanpat Jain , Edward Uchio , Harvey Risch , William W. Li , and Carolyn K. Wells Relevance of Molecular Markers in Prostate Cancer John Concato , Edward Uchio , and Carolyn K. Wells Relevance of Molecular Markers in Prostate Cancer Edward P. Gelmann and Susan M. Henshall Metrics Cited ByNew concepts concerning prostate cancer screeningHOXC8 Inhibits Androgen Receptor Signaling in Human Prostate Cancer Cells by Inhibiting SRC-3 Recruitment to Direct Androgen Target GenesRelevance of Molecular Markers in Prostate CancerJohn Concato, MD, MPH, Edward Uchio, MD, and Carolyn K. Wells, MPH 5 May 2009Volume 150, Issue 9Page: 647-649KeywordsBiopsyCancer screeningCancer treatmentPathologistsProstate cancerRadical prostatectomyStaining ePublished: 5 May 2009 Issue Published: 5 May 2009 CopyrightCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...